JP2014510094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510094A5 JP2014510094A5 JP2014500486A JP2014500486A JP2014510094A5 JP 2014510094 A5 JP2014510094 A5 JP 2014510094A5 JP 2014500486 A JP2014500486 A JP 2014500486A JP 2014500486 A JP2014500486 A JP 2014500486A JP 2014510094 A5 JP2014510094 A5 JP 2014510094A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- dosage form
- pharmaceutical dosage
- solid oral
- oral pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013268 sustained release Methods 0.000 claims 68
- 239000012730 sustained-release form Substances 0.000 claims 68
- 239000002552 dosage form Substances 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 52
- 239000007787 solid Substances 0.000 claims 46
- 238000009472 formulation Methods 0.000 claims 27
- 239000011159 matrix material Substances 0.000 claims 27
- -1 vegitramide Chemical compound 0.000 claims 24
- 239000013543 active substance Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 17
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 13
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 13
- 238000000518 rheometry Methods 0.000 claims 13
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 11
- 229960000240 hydrocodone Drugs 0.000 claims 11
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 11
- 239000000014 opioid analgesic Substances 0.000 claims 10
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 7
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 claims 6
- 229960002764 hydrocodone bitartrate Drugs 0.000 claims 6
- 238000010828 elution Methods 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 238000013265 extended release Methods 0.000 claims 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 4
- 229960001410 hydromorphone Drugs 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 238000005336 cracking Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- JMBRWJAVUIITGV-LNNMZZBZSA-N hydrocodone bitartrate Chemical compound [H+].[H+].[H+].[H+].O.O.O.O.O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC JMBRWJAVUIITGV-LNNMZZBZSA-N 0.000 claims 3
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- LIHDYIAAKPQZSN-UHFFFAOYSA-N 2,5-dihydroxy-5-methyl-3-(morpholin-4-ylamino)cyclopent-2-en-1-one Chemical compound O=C1C(C)(O)CC(NN2CCOCC2)=C1O LIHDYIAAKPQZSN-UHFFFAOYSA-N 0.000 claims 2
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 2
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- 239000008896 Opium Substances 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 2
- 229960001113 butorphanol Drugs 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 2
- 229950003851 desomorphine Drugs 0.000 claims 2
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 2
- 229960003701 dextromoramide Drugs 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 229960003461 dezocine Drugs 0.000 claims 2
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 2
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 2
- 229960002500 dipipanone Drugs 0.000 claims 2
- 238000007907 direct compression Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 2
- 229950010920 eptazocine Drugs 0.000 claims 2
- 229960004578 ethylmorphine Drugs 0.000 claims 2
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 2
- 229950004155 etorphine Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 238000007373 indentation Methods 0.000 claims 2
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 2
- 229950009272 isomethadone Drugs 0.000 claims 2
- 229960003029 ketobemidone Drugs 0.000 claims 2
- 229960003406 levorphanol Drugs 0.000 claims 2
- IMYHGORQCPYVBZ-UHFFFAOYSA-N lofentanyl Chemical group C1CN(CCC=2C=CC=CC=2)CC(C)C1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 IMYHGORQCPYVBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000365 meptazinol Drugs 0.000 claims 2
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 238000000465 moulding Methods 0.000 claims 2
- 229960004300 nicomorphine Drugs 0.000 claims 2
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 2
- 229950011519 norlevorphanol Drugs 0.000 claims 2
- 229960004013 normethadone Drugs 0.000 claims 2
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 2
- 229950007418 norpipanone Drugs 0.000 claims 2
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 229960001027 opium Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 2
- 229950004540 phenadoxone Drugs 0.000 claims 2
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 2
- 229950011496 phenomorphan Drugs 0.000 claims 2
- 229960004315 phenoperidine Drugs 0.000 claims 2
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 2
- 229950004345 properidine Drugs 0.000 claims 2
- 229960004739 sufentanil Drugs 0.000 claims 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| US61/467,824 | 2011-03-25 | ||
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510094A JP2014510094A (ja) | 2014-04-24 |
| JP2014510094A5 true JP2014510094A5 (enExample) | 2014-12-04 |
| JP5964940B2 JP5964940B2 (ja) | 2016-08-03 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014500486A Active JP5964940B2 (ja) | 2011-03-25 | 2012-03-22 | 制御放出性医薬剤形 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (enExample) |
| EP (1) | EP2688556B1 (enExample) |
| JP (1) | JP5964940B2 (enExample) |
| KR (1) | KR101619579B1 (enExample) |
| CN (1) | CN103547259A (enExample) |
| AU (1) | AU2012235878B2 (enExample) |
| BR (1) | BR112013024585A8 (enExample) |
| CA (1) | CA2831218C (enExample) |
| CY (1) | CY1116579T1 (enExample) |
| DK (1) | DK2688556T3 (enExample) |
| ES (1) | ES2544735T3 (enExample) |
| HR (1) | HRP20150835T1 (enExample) |
| HU (1) | HUE026981T2 (enExample) |
| IL (1) | IL228441B (enExample) |
| ME (1) | ME02189B (enExample) |
| MX (1) | MX350875B (enExample) |
| PH (1) | PH12013501994A1 (enExample) |
| PL (1) | PL2688556T3 (enExample) |
| PT (1) | PT2688556E (enExample) |
| RS (1) | RS54152B1 (enExample) |
| SI (1) | SI2688556T1 (enExample) |
| SM (1) | SMT201500209B (enExample) |
| WO (1) | WO2012131463A2 (enExample) |
| ZA (1) | ZA201307862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| BR0115382A (pt) | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| CN104873455B (zh) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| IN2014DN09238A (enExample) | 2012-04-17 | 2015-07-10 | Purdue Pharma Lp | |
| KR20150059167A (ko) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | 제어된 방출을 위한 남용 제지 약학적 조성물 |
| SG11201506064UA (en) | 2013-02-05 | 2015-08-28 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| BR112019027889A2 (pt) | 2017-06-30 | 2020-07-07 | Purdue Pharma L.P. | método de tratamento e formas de dosagem do mesmo |
| EP3675842A4 (en) * | 2017-08-31 | 2021-05-19 | Purdue Pharma L.P. | PHARMACEUTICAL DOSAGE FORMS |
| AU2018390826B2 (en) | 2017-12-20 | 2024-09-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| PT1251832E (pt) * | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| BR0115382A (pt) * | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| JP5259183B2 (ja) * | 2004-07-01 | 2013-08-07 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 乱用に対して保護された経口剤形 |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| CA2605180A1 (en) * | 2005-04-19 | 2006-10-26 | Alza Corporation | Controlled delivery dosage form of tramadol and gabapentin |
| WO2007133150A1 (en) * | 2006-05-17 | 2007-11-22 | Sandvik Intellectual Property Ab | A top hammer rock-drilling tool, a drill rod and coupling sleeve |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8241993B2 (en) * | 2007-07-13 | 2012-08-14 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510094A5 (enExample) | ||
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| CA2913368C (en) | Abuse deterrent immediate release formulation | |
| JP2009529046A5 (enExample) | ||
| CA2659523C (en) | Multilayer orally disintegrating tablet | |
| CA2661573A1 (en) | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic | |
| JP2006524249A5 (enExample) | ||
| JP2009545561A5 (enExample) | ||
| US20150005334A1 (en) | Abuse deterrent compositions and methods of use | |
| JP2008528534A5 (enExample) | ||
| RU2010106202A (ru) | Составы неопиоидных и ограниченных опиоидных аналгетиков | |
| JP2010501543A5 (enExample) | ||
| JP2015500273A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| TW201811332A (zh) | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 | |
| CA2652981A1 (en) | Robust sustained release formulations | |
| EP2968178A1 (en) | Pharmaceuticals comprising a ph-dependent component and ph-raising agent | |
| WO2009015734A2 (en) | Dosage form comprising immediate release naproxen and sustained release opioid analgesic | |
| JP2021500316A5 (enExample) | ||
| US10736874B1 (en) | Methods for treating pain associated with sickle cell disease | |
| EP2046300B1 (en) | Multilayer orally disintegrating tablet | |
| HRP20141001T1 (hr) | Farmaceutski sferoidi | |
| US11571390B2 (en) | Abuse deterrent compositions and methods of use | |
| EP3193873A1 (en) | Orally administrable compositions and methods of deterring abuse by intranasal administration | |
| HK1128881B (en) | Multilayer orally disintegrating tablet |